IR
GILD icon

Invictus RG’s Gilead Sciences GILD Stock Holding History

Invictus RG’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,787
Closed -$388K – 336
2017
Q3 		$388K Buy
4,787
+1,158
+32% +$88.5K 0.35% 106
2017
Q2 		$257K Buy
3,629
+3,061
+539% +$204K 0.19% 220
2017
Q1 		$39K Buy
+568
New +$39.9K 0.03% 554

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invictus RG's GILD Position: Q4 2017 in Review

Invictus RG sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 4,787 shares — an estimated $388K sold.

Invictus RG first reported a position in GILD in Q1 2017 and held it in 3 quarters. The position peaked at $388K in Q3 2017. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

  • Invictus RG reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
  • Invictus RG sold 4,787 Gilead Sciences shares in Q4 2017, an estimated $388K.
  • Invictus RG first reported a position in Gilead Sciences in Q1 2017 and held it in 3 quarters.
  • Invictus RG's Gilead Sciences position peaked at $388K in Q3 2017.
  • 1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Invictus RG's 13F filing for Q4 2017, filed 13 Feb 2018.